The paper published June 19 in Nature Genetics that described a genome-wide analysis to narrow down the implicated pathogenic signaling pathways and “prioritize drug targets for IgA nephropathy [IgAN]” no doubt proved of great interest to developers, plenty of which are busy in the space.
Wuhan LL Science & Technology Development Co. Ltd. has synthesized mannan-binding lectin serine protease 2 (MASP2) inhibitors reported to be useful for the treatment of lupus nephritis and IgA nephropathy, among others.
Maze Therapeutics Inc. has identified apolipoprotein L1 (APOL1) inhibitors reported to be useful for the treatment of chronic kidney disease, focal segmental glomerulosclerosis, diabetic, hypertensive, HIV-associated nephropathy, lupus nephritis, pre-eclampsia and sepsis.
Biocity Biopharmaceutics Co. Ltd. is advancing its pipeline of differentiated, modality-independent therapeutics for oncology that include small molecules, monoclonal and bispecific antibodies, as well as antibody-drug conjugates (ADCs). The Wuxi, China-headquartered company is focused on first-in-class molecules for different modalities that can be combined with other treatments, Biocity Co-founder and Executive Vice President Ivy Wang told BioWorld.
Biocity Biopharmaceutics Co. Ltd. is advancing its pipeline of differentiated, modality-independent therapeutics for oncology that include small molecules, monoclonal and bispecific antibodies, as well as antibody-drug conjugates (ADCs). The Wuxi, China-headquartered company is focused on first-in-class molecules for different modalities that can be combined with other treatments, Biocity Co-founder and Executive Vice President Ivy Wang told BioWorld.
Scientists behind Purespring Therapeutics Ltd. have made progress in overcoming the problems of accessibility, complexity of structure and diversity of cell types that have held back the use of gene therapy in the kidneys, reporting success in treating nephrotic syndrome in a mouse model of the inherited form of the renal disease.
Gri Bio Inc. reported data on its type 2 natural killer T (NKT) cell activator GRI-0803 at the Autoimmunity Conference hosted by FASEB earlier in August. The company is developing GRI-0803 in autoimmune diseases, with an initial focus of systemic lupus erythematosus (SLE).
Biohaven Ltd. is advancing development of its first-in-class bispecific IgG degrader, BHV-1300, which has potential to treat multiple immune-mediated diseases. The pan-IgG degrader has demonstrated a competitive safety, manufacturable and pharmacodynamic profile, and BHV-1300 dosage regimens are expected to allow co-administration with existing standards of care. An IND submission is planned for the second half of this year.
Researchers from Anhui Medical University (AMU) presented data from a study that aimed to assess the role of gastrin-releasing peptide (GRP) and its receptor GRPR in acute kidney injury (AKI).
Mediwhale Inc. and Yonsei University College of Medicine, Seoul, Republic of Korea, are developing a new predicting tool combining artificial intelligence (AI) and non-invasive retinal eye examination capable of accurately predicting chronic kidney diseases before symptoms appears.
RSS
